Seattle Genetics (SGEN) Tops Q3 EPS by 8c, Offers FY Guidance
Tweet
Share
E-mail
Get Alerts SGEN Hot Sheet
Price: $228.74 --0%
Financial Fact:
Revenue from collaboration and license agreements: 23.97M
Today's EPS Names:
VIVE, ENSV, MDLM, More
Financial Fact:
Revenue from collaboration and license agreements: 23.97M
Today's EPS Names:
VIVE, ENSV, MDLM, More
Join SI Premium – FREE
Seattle Genetics (NASDAQ: SGEN) reported Q3 EPS of ($0.34), $0.08 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $135.3 million versus the consensus estimate of $112.81 million.
2017 Financial Outlook
Seattle Genetics updated its full year 2017 financial guidance as follows:
| Current | Previous | |||||||
| Revenues from collaboration and license agreements | $90 million to $100 million | $75 million to $90 million | ||||||
| Royalty revenues | $60 million to $65 million | $50 million to $55 million | ||||||
| Research and development expenses | $460 million to $480 million | $460 million to $500 million |
For earnings history and earnings-related data on Seattle Genetics (SGEN) click here
.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HealthEquity (HQY) Tops Q2 EPS by 5c ; Offers Guidance
- Best Buy (BBY) Tops Q2 EPS by 12c, Offers Guidance
- Dollar Tree (DLTR) Tops Q2 EPS by $1.59, Beats on Revenue; Offers FY Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
